Effectiveness of adjuvant chemotherapy in patients with Stage II colorectal cancer: A multicenter retrospective study

Journal of Research in Medical Sciences

Volumn 24, Issue 1, 2019, Pages

  Jalaeikhoo, Hasan ^a   Zokaasadi, Mohammad ^a   Khajeh Mehrizi, Ahmad ^b   Rajaeinejad, Mohsen ^a   Mousavi, Seied Asadollah ^b   Vaezi, Mohammad ^b   Fumani, Hosein Kmranzadeh ^b   Keyhani, Manoutchehr ^c   Alimoghaddam, Kamran ^b   Ghavamzadeh, Ardeshir ^b  

^a AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant chemotherapy; Colorectal neoplasms; Survival

Indexed keywords

CAPECITABINE; FOLINIC ACID; OXALIPLATIN;

ABDOMINAL BLEEDING; ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADULT; ANEMIA; ARTICLE; ASCENDING COLON; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLON ADENOCARCINOMA; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DESCENDING COLON; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE OBSTRUCTION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSTRUCTION; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PERFORATION; PERINEURAL INVASION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURGICAL MARGIN; TRANSVERSE COLON; TUMOR VOLUME;

EID: 85071679404     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: 10.4103/jrms.JRMS_106_18     Document Type: Article

References (30)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Mirzaei H, Salehi H, Sahebkar A, Avan A, Jaafari MR, Namdar A, et al. Deciphering biological characteristics of tumorigenic subpopulations in human colorectal cancer reveals cellular plasticity. J Res Med Sci 2016;21:64.
3. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fuorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
4. Jalaeikhoo H, Khajeh-Mehrizi A, Zokaasadi M, Rajaeinejad M, Asadollah Mousavi S, Vaezi M, et al. Sixteen years of experience with the treatment of advanced colorectal cancer in Iran; A report from three institutions. Middle East J Dig Dis 2018;10:160-8.
5. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fuorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
6. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fuorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007;25:2198-204.
7. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007;370:2020-9.
8. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008(3):CD005390.
9. National Comprehensive Cancer Network Guidelines. Available from: nccn.org/professionals/physician-gls/pdf/colon.pdf. [Last accessed on 2017 May 15].
10. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19.
11. Labianca R, Nordlinger B, Bereta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi64-72.
12. O'Connor ES, Greenblat DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011;29:3381-8.
13. Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer 2015;121:527-34.
14. Artac M, Turhal NS, Kocer M, Karabulut B, Bozcuk H, Yalcin S, et al. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. Tumori 2014;100:143-8.
15. Cakar B, Varol U, Junushova B, Muslu U, Gursoy Oner P, Gokhan Surmeli Z, et al. Evaluation of the efcacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer. J BUON 2013;18:372-6.
16. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28:264-71.
17. De Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, et al. High-dose folinic acid and 5-fuorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988;24:1499-503.
18. Booth CM, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, et al. Adjuvant chemotherapy for stage II colon cancer: Practice paterns and efectiveness in the general population. Clin Oncol (R Coll Radiol) 2017;29:e29-38.
19. Glimelius B, Dahl O, Cedermark B, Jakobsen A, Benten SM, Starkhammar H, et al. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005;44:904-12.
20. Jee SH, Moon SM, Shin US, Yang HM, Hwang DY. Efectiveness of adjuvant chemotherapy with 5-FU/Leucovorin and prognosis in stage II colon cancer. J Korean Soc Coloproctol 2011;27:322-8.
21. Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV, et al. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer 2016;122:3277-87.
22. Wu X, Zhang J, He X, Wang C, Lian L, Liu H, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: A systematic review of 12 randomized controlled trials. J Gastrointest Surg 2012;16:646-55.
23. Sato H, Maeda K, Sugihara K, Mochizuki H, Kotake K, Teramoto T, et al. High-risk stage II colon cancer after curative resection. J Surg Oncol 2011;104:45-52.
24. Sanof HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial diferences in advanced colorectal cancer outcomes and pharmacogenetics: A subgroup analysis of a large randomized clinical trial. J Clin Oncol 2009;27:4109-15.
25. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
26. Nazemalhosseini Mojarad E, Kashf SM, Mirtalebi H, Taleghani MY, Azimzadeh P, Savabkar S, et al. Low level of microsatellite instability correlates with poor clinical prognosis in stage II colorectal cancer patients. J Oncol 2016;2016:2196703.
27. Bertagnolli MM, Niedzwiecki D, Hall M, Jewell SD, Mayer RJ, Goldberg RM, et al. Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. J Clin Oncol 2009;27:4012.
28. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29:1261-70.
29. Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the multicenter international study of oxaliplatin, fuorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol 2012;30:3353-60.
30. Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768-74.